Elevance Health (NYSE:ELV – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday. A number ...

Elevance Health’s Executive VP Charles Kendrick sold $1.4M worth of stock, reducing his stake by 40%. While insider sales can ...

Regulatory changes under Trump's administration and AI integration are key factors influencing Elevance Health's future ...

Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ...

Elevance Health jumped 3.1% in the last session, extending its six-day rally. The surge was fueled by investor optimism, a ...

Elevance Health ELV -2.57% + Free Alerts has outperformed the market over the past 15 years by 2.24% on an annualized basis producing an average annual return of 13.22%. Currently, Elevance Health has ...

Shares of Elevance Health Inc. ELV shed 2.61% to $411.04 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to 5,599.30 ...

Student-led awareness raising campaigns are a great way to reach people because students often have the trust of the ...

Elevance Health, Inc. (ELV), with a market cap of $89.92 billion, is a leading health benefits company in the United States.

Humana competes with other major players in the healthcare space, including UnitedHealth Group (NYSE:UNH), Elevance Health, and CVS Health (NYSE:CVS). The competitive landscape remains intense, with ...

Earnings per share (EPS) missed analyst estimates by 5.2%. The primary driver behind last 12 months revenue was the Health Benefits segment contributing a total revenue of US$150.3b (85% of total ...